title: [Changes in weight and diabetes compensation (HbA1c) in patients with diabetes mellitus type 2 after adding exenatide (Byetta) to the current treatment in 28 diabetology departments in the Czech Republic -  BIBYII study (observations lasting 24 months)].
abstract: BIBYII STUDY OBJECTIVE: To obtain experience with longterm (24 months) exenatide treatment (Byetta) in patients with diabetes mellitus type 2 from a common clinical practice of diabetology departments in the Czech Republic. TYPE OF OBSERVATION: Observational study conducted by a randomly selected group of outpatient medical practitioners from 28 diabetology departments in the Czech Republic. OBSERVED AND ASSESSED POPULATION: From the original population of 465 patients, who underwent a minimum of three months Byetta treatment, 169 patients (36.6%) remained during the second prolonged observation after 18 months, and 76 patients completed 24 months of uninterrupted Byetta treatment. The following basic information about the patients was collected: year of birth, sex, age when diabetes mellitus (DM) manifested, height, maximum weight before diabetes and when DM manifested. The study recorded the following values in three- month intervals: weight, waistline, glycated haemoglobin (HbA1c), and DM treatment. The population of the prolonged observation comprised 50.3% women and 49.7 % men, and the average age at the time of DM2 manifestation was 48.0 (20- 73 years).
  
  
  RESULTS
  At the beginning of Byetta treatment, the average maximum BMI in the subpopulation observed for 24 months was 38.44; after 3, 6, 9, 12 and 24 months the following levels were measured, respectively: 36.79, 36.22, 35.91, 35.57 and 35.58. The original HbA1c level of 7.44% at the beginning of Byetta treatment decreased after 3, 6, 9, 12 and 24 months to 6.33, 5.98, 5.83, 5.86 and 5.93%.
  
  
  CONCLUSIONS
  Adding Byetta to the currently applied treatment of obese patients with diabetes mellitus type 2 over a period of 24 months has led to an improvement in HbA1c level by 1.51%, and BMI level was reduced by 2.37 after two years of Byetta treatment.
authors.affiliation: Interni Klinika, Lekarske Fakulty UK a FN Motol, Praha. jindra.perusicova@seznam.cz
authors.forename: J
authors.initials: J
authors.lastname: Perušičová
authors.forename: P
authors.initials: P
authors.lastname: Piťhová
authors.forename: I
authors.initials: I
authors.lastname: Haladová
authors.forename: A Pracovní Skupina
authors.initials: AP
authors.lastname: Diabetologů
authors.forename: D
authors.initials: D
authors.lastname: Acsová
authors.forename: J
authors.initials: J
authors.lastname: Bělobrádková
authors.forename: A
authors.initials: A
authors.lastname: Belzová
authors.forename: K
authors.initials: K
authors.lastname: Berková
authors.forename: B
authors.initials: B
authors.lastname: Doležalová
authors.forename: H
authors.initials: H
authors.lastname: Dvořáková
authors.forename: K
authors.initials: K
authors.lastname: Hejnicová
authors.forename: M
authors.initials: M
authors.lastname: Hudcová
authors.forename: D
authors.initials: D
authors.lastname: Kallmünzerová
authors.forename: Z
authors.initials: Z
authors.lastname: Krejsová
authors.forename: G
authors.initials: G
authors.lastname: Markofová
authors.forename: H
authors.initials: H
authors.lastname: Müllerová
authors.forename: K
authors.initials: K
authors.lastname: Owen
authors.forename: M
authors.initials: M
authors.lastname: Pelikánová
authors.forename: L
authors.initials: L
authors.lastname: Raclavská
authors.forename: E
authors.initials: E
authors.lastname: Račická
authors.forename: O
authors.initials: O
authors.lastname: Skarpová
authors.forename: A
authors.initials: A
authors.lastname: Váchová
authors.forename: A
authors.initials: A
authors.lastname: Veselá
authors.forename: J
authors.initials: J
authors.lastname: Vyoralová
authors.forename: J
authors.initials: J
authors.lastname: Brož
authors.forename: T
authors.initials: T
authors.lastname: Edelsberger
authors.forename: M
authors.initials: M
authors.lastname: Honka
authors.forename: T
authors.initials: T
authors.lastname: Hrdina
authors.forename: P
authors.initials: P
authors.lastname: Chmura
authors.forename: J
authors.initials: J
authors.lastname: Tosovsky
mesh_terms: D000328:Adult; D000368:Aged; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D000077270:Exenatide; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000627:therapeutic use*; D014688:Venoms / Q000627:therapeutic use*; D015431:Weight Loss; D055815:Young Adult
chemical_list: D000077270:Exenatide; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D010455:Peptides; D014688:Venoms